Mestastop Solutions, a Bengaluru-based cancer drug discovery startup, has signed a Memorandum of Understanding (MoU) with Vipragen Biosciences, a contract research organisation (CRO) based in Mysuru, specialising in preclinical drug discovery and development services.

Under this agreement, Vipragen and Mestastop will collaborate to improve the extensive oncology services of Vipragen, being delivered to their global customers, by using proprietary Mestastop platforms.

The MoU establishes the terms and conditions under which the two parties will collaborate for novel drug discovery, drug repurposing, and profiling current anti-cancer leads or candidates for their anti-metastatic effects.

The primary mission of this collaboration would be to represent each other’s services for comprehensive solutions around cancer and metastasis. Each party would retain ownership of the respective intellectual property it brings into the collaboration.

Discussing this matter, Dr S Chandrashekaran, the Chairman and Managing Director of Vipragen, expressed, "Vipragen has been in the drug discovery sector for over a decade, collaborating with numerous clients in the oncology field. This partnership is exceptionally distinctive and strategic, leveraging Vipragen’s vivarium and harnessing Mestastop’s proprietary platforms to facilitate metastasis drug discovery and early predictive diagnostics."

Dr Arnab Roy Chowdhury, Founder and Director of Mestastop added, " To partner with an established CRO like Vipragen, is a validation of our unique platforms and jointly allows us to empower Biotech and Pharma looking for novel solutions to fight cancer".